These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32067534)

  • 1. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
    Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
    J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
    Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
    Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
    Chow PK; Gandhi M; Gebski V
    Future Oncol; 2017 Oct; 13(25):2213-2216. PubMed ID: 28976206
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
    J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
    Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
    Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil.
    Agirrezabal I; Pereira Grillo Junior LS; Nasser F; Brennan VK; Bugano D; Galastri FL; da-Silva ALFA; Shergill S; da Motta-Leal-Filho JM
    J Med Econ; 2023; 26(1):731-741. PubMed ID: 37139828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials.
    Pollock RF; Brennan VK; Shergill S; Colaone F
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):341-349. PubMed ID: 33131346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry.
    Lee RC; Liang PC; Liang HL; Chen YF; Yu CY; Cheng PN; Hung CF; Hsia CY; Lai HC; Ho MC; Cheng YF; Liu YS; Chao Y; Chen CH
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1318-1327. PubMed ID: 38615197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK.
    Brennan VK; Colaone F; Shergill S; Pollock RF
    J Med Econ; 2020 Dec; 23(12):1588-1597. PubMed ID: 33084466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
    Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
    Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
    [No Abstract]   [Full Text] [Related]  

  • 16. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Adverse Event Profile of TheraSphere
    Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
    Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
    Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma.
    Feng X; Zhang L; Niu H; Zhang H; Yang L; Wen Y; Chen SY; Shi Y; He Z; Yu L; Wang Y; Huang X; Wang Z; Qin M; Wen X; Zhang Z; Song J; Zheng Z; Yin H; Zhang H; Ma L; Wei J; Wu X; Zhang L; Zhao Y; Lu Q; Xiao H; Liu T; Fang P; Wei L; Gandhi RT; Dong J
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):319-322. PubMed ID: 36658669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.